New pill aims to slow lung scarring in IPF patients

NCT ID NCT06747923

Recruiting now Disease control Sponsor: SPARK Biopharma Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called SB17170 in 30 adults with moderate to severe idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either the drug or a placebo daily for 12 weeks. The main goal is to see if the drug improves lung function, measured by how much air they can exhale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SB17170 (an experimental oral drug)
What this could lead to: If successful, this could point toward a new treatment option to slow lung function decline in people with idiopathic pulmonary fibrosis.
What could go wrong: This is an early Phase 2a trial with only 30 participants, so results may not apply broadly. The drug may not improve lung function or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS IDIOPATHIC PULMONARY FIBROSIS (IPF) IPF

Contacts and locations

Locations

Ajou University Hospital
NOT_YET_RECRUITING

Suwon, South Korea
Chung-Ang University Gwangmyeong Hospital
RECRUITING

Gwangmyeong, South Korea
Myong Ji Hospital
RECRUITING

Goyang, South Korea
Seoul Asan Hospital
NOT_YET_RECRUITING

Seoul, South Korea
The Catholic Univ. of Korea Seoul St. Mary's Hospital
NOT_YET_RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.